Newsroom

8 October 2012
Sangart Completes Patient Enrollment in Phase 2b Clinical Trial of MP4OX in Traumatic Hemorrahagic Shock Patients

24 May 2012
Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis of Phase 2b Study of MP4OX in Severe Trauma Patients with Hemorrhagic Shock

15 February 2012
Sangart Enhances Leadership Team Bringing Superior Depth of Expertise

12 January 2012
Sangart Initiates Phase 1b Study of MP4CO in Patients with Sickle Cell Disease

14 June 2011
Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients with Hemorrhagic Shock

19 April 2011
Sangart Announces Closing of $50 Million Series G Financing

19 January 2011
Sangart, Inc. Presents Severe Traumatic Hemorrhage Phase IIa Clinical Trial Results at Key Meetings

06 December 2010
Sangart, Inc. Announces Cooperative Research and Development Agreement with the U.S. Navy to Evaluate MP4 molecule in Traumatic Brain Injury

15 November 2010
Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease

06 October 2010
Sangart, Inc. Receives $1.1 Million Grant Award From The United States Department Of Defense For Further Development Of MP4 Molecule In Trauma

05 October 2010
Sangart Secures $15 Million in Funding to Advance Clinical Research and Development

31 August 2010
Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients - Study Meets Primary Endpoint of Reducing Lactate Levels in Trauma Patients

29 June 2010
Sangart, Inc. Completes Enrollment in Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

22 April 2010
Data Safety Monitoring Board Recommends Continuation of Sangart's Phase IIa Trial for Oxygen Therapeutic MP4OX in Severe Trauma Patients - Clinical Trial Enrollment Remains on Track

December 09
Sangart, Inc. Featured in Broadcast Segment

09 December 09
Sangart, Inc. Receives Orphan Drug Designation for the Use of MP4CO in Patients with Sickle Cell Disease

09 December 09
Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent

27 May 09
Sangart, Inc. Announces Opening of European Office - New Senior Management Addition To Team

12 Mar 09
Sangart, Inc. Completes Series F Funding Round

7 Jan 09
Sangart, Inc. Announces Key Executive Appointments and Company Restructuring – Business Units Refocused on Additional Clinical Studies Planned for Hemospan

11 Jun 08
Sangart Responds to Report Published in the Journal Of The American Medical Association and Provides Update on Phase III Clinical Trials of Hemospan

19 May 08
Sangart, Inc. Completes Enrollment In Second Phase III Study of Hemospan, A Novel Oxygen Transport Agent

24 Mar 08
Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan

11 Mar 08
Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan® Following Second Interim Review

07 Jan 08
Sangart, Inc. Initiates Dosing In Phase II Study Of Hemospan® In Chronic Critical Limb Ischemia

12 Dec 07
Independent Data Safety Monitoring Board Recommends Continuation of Sangart's Pivotal Phase III Trials of Hemospan®

04 Apr 07
Sangart, Inc. Announces Closing of $50M Series F Financing

13 Feb 07
Sangart, Inc. Initiates Phase III Clinical Trials

20 Dec 06
Sangart Announces Publication of Phase II Study Results in The Journal of the American Society of Anesthesiologists - Anesthesiology

13 Dec 05
Sangart Announces Issuance of Patent for Hemospan® Oxygen Transport Agent

01 Nov 05
Sangart Announces Positive Phase II Results for Hemospan® Oxygen Transport Agent; Presentation of Results at 35th Critical Care Congress

25 Jul 05
Sangart Announces New Facility Plans

19 Jul 05
Sangart Initiates Phase II Clinical Trial for Hemospan®

24 Feb 05
Sangart Completes Enrollment in Phase II Clinical Study of Hemospan®

08 Sep 04
Sangart Initiates Phase II Clinical Trial For Hemospan® And Announces New Grant Funding

12 Apr 04
Sangart Receives Approval To Initiate Phase II Clinical Trial For Hemospan

11 Mar 04
Sangart Reports Positive Phase Ib/II Clinical Trial Results for Hemospan ®

05 Sep 03
Sangart Closes Preferred Stock Private Placement

23 Jul 03
Sangart Publishes Results of Resuscitation Study

08 May 03
Sangart Publishes Study of Hemospan (MP4) in Transfusion

13 Dec 02
Sangart Receives Approval to Initiate Phase Ib/II Clinical Trial for Hemospan®

03 Dec 02
Sangart to Present at American Society of Hematology Annual Meeting

21 Oct 02
Sangart to Present at the American Association of Blood Banks (AABB) Annual Meeting

27 Aug 02
Sangart Awarded Patent for Blood Substitute Product

22 Aug 02
Sangart to Present at 27th Congress of The International Society of Blood Transfusion

07 Aug 02
Gambro - Reaches milestone in PET Technology R&D

02 Aug 02
Sangart Reports Positive Phase I Data For Its New Generation Oxygen Transport Agent - Hemospan®

01 Feb 02
New Director Elected to Sangart's Board

27 Jul 01
Sangart and Gambro Enter Into Strategic Partnership